MNA
AZN icon

Manning & Napier Advisors’s AstraZeneca AZN Stock Holding History

Manning & Napier Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-770,712
Closed -$143M – 618
2025
Q4 		$143M Sell
770,712
-110,385
-13% -$19.4M 1.85% 14
2025
Q3 		$135M Sell
881,097
-195,171
-18% -$29.5M 1.72% 18
2025
Q2 		$150M Sell
1,076,268
-451,346
-30% -$63.3M 1.79% 15
2025
Q1 		$225M Sell
1,527,614
-345,152
-18% -$49.9M 2.77% 6
2024
Q4 		$245M Buy
1,872,766
+282,149
+18% +$39.5M 2.8% 6
2024
Q3 		$248M Buy
1,590,617
+382,281
+32% +$61.7M 2.73% 6
2024
Q2 		$188M Buy
+1,208,336
New +$182M 2.13% 10
2017
Q1 		– Sell
-247,980
Closed -$13.5M – 330
2016
Q4 		$13.5M Hold
247,980
– – 0.09% 103
2016
Q3 		$16.3M Buy
247,980
+4,095
+2% +$268K 0.1% 79
2016
Q2 		$14.7M Hold
243,885
– – 0.09% 87
2016
Q1 		$13.7M Buy
243,885
+13,965
+6% +$839K 0.08% 96
2015
Q4 		$15.6M Buy
229,920
+2,050
+0.9% +$134K 0.09% 95
2015
Q3 		$14.5M Hold
227,870
– – 0.08% 119
2015
Q2 		$14.5M Hold
227,870
– – 0.06% 126
2015
Q1 		$15.6M Hold
227,870
– – 0.07% 131
2014
Q4 		$16M Sell
227,870
-89,310
-28% -$6.39M 0.07% 130
2014
Q3 		$22.7M Buy
317,180
+8,150
+3% +$597K 0.09% 115
2014
Q2 		$23M Sell
309,030
-150,539
-33% -$10.9M 0.09% 117
2014
Q1 		$29.8M Sell
459,569
-31,309
-6% -$2.02M 0.12% 100
2013
Q4 		$29.1M Sell
490,878
-18,067
-4% -$981K 0.13% 93
2013
Q3 		$26.4M Sell
508,945
-2,722
-0.5% -$137K 0.12% 92
2013
Q2 		$24.2M Buy
+511,667
New +$26.1M 0.13% 91

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Manning & Napier Advisors's AZN Position: Q1 2026 in Review

Manning & Napier Advisors sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 770,712 shares — an estimated $143M sold.

Manning & Napier Advisors first reported a position in AZN in Q2 2013 and held it in 22 quarters. The position peaked at $248M in Q3 2024. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Manning & Napier Advisors reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Manning & Napier Advisors sold 770,712 AstraZeneca shares in Q1 2026, an estimated $143M.
  • Manning & Napier Advisors first reported a position in AstraZeneca in Q2 2013 and held it in 22 quarters.
  • Manning & Napier Advisors's AstraZeneca position peaked at $248M in Q3 2024.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Manning & Napier Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.